GRAL
NASDAQ HealthcareGRAIL, Inc. - Common Stock
Diagnostics & Research
GRAIL, Inc., a commercial-stage healthcare company, provides multi-cancer early detection testing and services in the United States and internationally. It offers Galleri, a cancer screening test for asymptomatic individuals over 50 years of age; and a diagnostic aid for cancer tests to accelerate diagnostic resolution for patients with clinical suspicion of cancer. The company also provides development services, including support for ongoing clinical studies, pilot testing, research, and therapy development. In addition, its precision oncology portfolio consists of n RUO-targeted methylation-based platform that enables applications for disease prognostication, risk stratification, minimal residual disease detection, and recurrence and relapse monitoring. The company was incorporated in 2015 and is headquartered in Menlo Park, California.
๐ Market Data
| Price | $71.96 |
|---|---|
| Volume | 429,790 |
| Market Cap | 3.09B |
| Beta | 3.220 |
| RSI (14-Day) | 63.0 |
| 200-Day MA | $74.04 |
| 50-Day MA | $65.02 |
| 52-Week High | $118.84 |
| 52-Week Low | $29.95 |
| Forward P/E | -7.41 |
| Price / Book | 1.18 |
๐ฏ Investment Strategy Scores
GRAL scores across each investment strategy. Higher is better for that strategy's goals.
๐ Strategy Interpretation
Best fit: ๐ Moon Shot (97/100) โ this strategy High growth potential (high beta + oversold).
Lowest fit among scored strategies: ๐ฐ Dividend Daddy (1/100). No single score is a buy or sell signal โ use multiple lenses together. Learn how to read these scores โ
๐ Learn More
Indicators on this page
Educational articles
Find GRAL in your text
Paste any article, transcript, or post โ the tool will extract GRAL and every other hidden ticker.
Disclaimer: This data is for educational and entertainment purposes only and does not constitute financial advice. Market data may be delayed. Always do your own research before making investment decisions.
Data last updated: 2026-07-16.